Revvity reports Q2 revenue, raises FY guide; expands diagnostics
Revvity (RVTY) reported Q2 revenue of $730M (pro forma +4%), raised FY guidance to $2.83–$2.86B (pro forma ~4–5% growth), and launched SuperFlex prenatal testing, expanded preeclampsia diagnostic coverage, and moved the T—SPOT.TB assay toward lab automation.
Revvity, Inc. (NYSE:RVTY) said Q2 revenue was $730M, with pro forma revenue up +4%. 86B, implying pro forma growth of ~4—5%. TB assay toward lab automation.